ArticleBrain : a journal of neurology2016

A de novo compound targeting α-synuclein improves deficits in models of Parkinson's disease.

Wolfgang Wrasidlo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.